RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY Putting It's Best Foot ForwardI can readily see the viewpoints of Ionc and Fox.
Many of us have a great deal tied up here.
But note the date: this piece came out in November, 2022. That was when the data first came out for the panc trial and before the Fast track designation.
ONCY does need to try and keep the retail price up as much as possible as part of keeping the ship afloat from November until the negotiations end somehow.
So while I would rather not have this kind of report be needed, it is part of getting the message out. Understanding clinical results is harder than almost any other investing information, and there is real complexity associated with those results. They need someone to tell the story. This piece came out around the time of the KOL seminar, which was also a more high brow version of getting the message out.